(ACRS) Aclaris Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00461U1051
ACRS: Cancer, Dermatitis, Autoimmune, Inflammatory, Disease
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates for immune-inflammatory diseases. Headquartered in Wayne, Pennsylvania, the company operates through two primary segments: Therapeutics and Contract Research. The Therapeutics segment concentrates on identifying and advancing therapeutic solutions for significant unmet medical needs in immuno-inflammatory diseases. The Contract Research segment provides specialized laboratory services, supporting external clients in their research endeavors.
The companys pipeline includes several promising drug candidates. Zunsemetinib (ATI-450), a novel MK2 inhibitor, is currently in Phase 1b/2 clinical trials for the treatment of metastatic breast and pancreatic cancer. ATI-1777, a soft JAK 1/3 inhibitor, has completed Phase 2b trials for moderate to severe atopic dermatitis and other dermatological conditions, showcasing potential in addressing inflammatory skin diseases. Additionally, ATI-2138, an oral covalent inhibitor targeting ITK and JAK3, is under Phase 1 evaluation for T cell-mediated autoimmune diseases, highlighting Aclaris commitment to innovative immunomodulatory therapies.
Founded in 2012, Aclaris Therapeutics has established itself as a dedicated player in the biopharmaceutical industry, with a strong emphasis on scientific rigor and patient-centric innovation. For more information, visit their website at https://www.aclaristx.com.
Three-Month Forecast: Based on the provided
Additional Sources for ACRS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ACRS Stock Overview
Market Cap in USD | 198m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2015-10-07 |
ACRS Stock Ratings
Growth 5y | 22.1% |
Fundamental | -50.4% |
Dividend | 0.0% |
Rel. Strength Industry | 34.5 |
Analysts | 4.14/5 |
Fair Price Momentum | 1.33 USD |
Fair Price DCF | - |
ACRS Dividends
No Dividends PaidACRS Growth Ratios
Growth Correlation 3m | -93.1% |
Growth Correlation 12m | 67.2% |
Growth Correlation 5y | -38.2% |
CAGR 5y | 12.24% |
CAGR/Max DD 5y | 0.13 |
Sharpe Ratio 12m | -0.04 |
Alpha | 16.93 |
Beta | 2.24 |
Volatility | 72.20% |
Current Volume | 945.6k |
Average Volume 20d | 629.5k |
As of March 15, 2025, the stock is trading at USD 1.56 with a total of 945,560 shares traded.
Over the past week, the price has changed by -14.75%, over one month by -33.05%, over three months by -48.34% and over the past year by +35.65%.
No, based on ValueRay Fundamental Analyses, Aclaris Therapeutics (NASDAQ:ACRS) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -50.35 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACRS as of March 2025 is 1.33. This means that ACRS is currently overvalued and has a potential downside of -14.74%.
Aclaris Therapeutics has received a consensus analysts rating of 4.14. Therefor, it is recommend to buy ACRS.
- Strong Buy: 3
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ACRS Aclaris Therapeutics will be worth about 1.6 in March 2026. The stock is currently trading at 1.56. This means that the stock has a potential downside of -0.64%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 9.8 | 530.1% |
Analysts Target Price | 10 | 541% |
ValueRay Target Price | 1.6 | -0.6% |